Physician profile
Michelle Walker
NPI 1235368291
$5,384.39
in general payments reported to CMS, 2019-2025
30 companies · $630 in 2025
The $630 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,141 · 2022: $1,416 · 2023: $1,208 · 2024: $989 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.56 |
| Education | $134.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,159.25 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $917.80 | 2021-2024 | Nucala, Trelegy Ellipta, Shingrix |
| Regeneron Healthcare Solutions, INC. | $661.62 | 2021-2024 | Dupixent |
| Optinose US, INC. | $383.26 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $253.19 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $243.05 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.89 | 2022-2024 | Takhzyro, Cuvitru |
| Genzyme Corporation | $193.16 | 2021-2024 | |
| Pfizer INC. | $143.97 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $138.12 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.82 | 2025 | Cobenfy |
| Kaleo, INC. | $130.28 | 2021-2023 | Auvi-Q |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Csl Behring | $106.43 | 2024 | Haegarda |
| Biocryst US Sales Co., LLC | $92.82 | 2022-2024 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $67.32 | 2022-2024 | |
| Genentech USA, INC. | $58.33 | 2021 | |
| Abbvie INC. | $48.53 | 2023-2025 | |
| Novo Nordisk INC | $45.88 | 2025 | Rybelsus, Ozempic |
| Grifols USA, LLC | $38.86 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.41 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.81 | 2021 | |
| Leo Pharma INC. | $25.35 | 2025 | Adbry |
| Pharming Healthcare, INC. | $23.96 | 2024 | Ruconest |
| Incyte Corporation | $22.83 | 2022 | |
| Corium, LLC | $21.57 | 2025 | Azstarys |
| Abbott Laboratories | $21.44 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $19.76 | 2025 | Rexulti |
| Amgen INC. | $17.10 | 2023 | Tezspire |
| Supernus Pharmaceuticals, INC. | $14.58 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.